GSK confirms closure of agreement to divest anaesthesia portfolio to Aspen
Issued: London UK
GlaxoSmithKline plc (LSE/NYSE: GSK) today announced the closure of an agreement with Aspen (JSE: APN) aligned with GSK’s strategy of simplification through focusing on core therapeutic areas.
GSK has divested its anaesthesia portfolio to Aspen (excluding the US and Canada which had been previously divested) for £180m plus milestones of up to £100m.
Notes to editors:
- GSK’s anaesthesia portfolio consists of Ultiva, Nimbex, Tracrium, Mivacron and Anectine.
- GSK 2016 full year sales of the anaesthesia portfolio were approximately £70 million.
GSK – one of the world’s leading research-based pharmaceutical and healthcare companies – is committed to improving the quality of human life by enabling people to do more, feel better and live longer. For further information please visit www.gsk.com/about-us.
|
GSK enquiries: |
|
|
|
|
UK Media enquiries: |
Simon Steel |
+44 (0) 20 8047 5502 |
(London) |
|
|
Anna Carruth |
+44 (0) 20 8047 5502 |
(London) |
|
|
|
|
|
|
US Media enquiries: |
Sarah Alspach |
+1 202 715 1048 |
(Washington, DC) |
|
|
Sarah Spencer |
+1 215 751 3335 |
(Philadelphia) |
|
|
|
|
|
|
Analyst/Investor enquiries: |
Tom Curry |
+ 1 215 751 5419 |
(Philadelphia) |
|
|
Gary Davies |
+44 (0) 20 8047 5503 |
(London) |
|
|
James Dodwell |
+44 (0) 20 8047 2406 |
(London) |
|
|
Jeff McLaughlin |
+1 215 751 7002 |
(Philadelphia) |
Cautionary statement regarding forward-looking statements
GSK cautions investors that any forward-looking statements or projections made by GSK, including those made in this announcement, are subject to risks and uncertainties that may cause actual results to differ materially from those projected. Such factors include, but are not limited to, those described under Item 3.D 'Risk factors' in the company's Annual Report on Form 20-F for 2015.
Registered in England & Wales:
No. 3888792
Registered Office:
980 Great West Road
Brentford, Middlesex
TW8 9GS
